BRPI0408777A - inibição seletiva da produção de estrogênio e provisão de efeitos estrogênicos no corpo humano - Google Patents

inibição seletiva da produção de estrogênio e provisão de efeitos estrogênicos no corpo humano

Info

Publication number
BRPI0408777A
BRPI0408777A BRPI0408777-1A BRPI0408777A BRPI0408777A BR PI0408777 A BRPI0408777 A BR PI0408777A BR PI0408777 A BRPI0408777 A BR PI0408777A BR PI0408777 A BRPI0408777 A BR PI0408777A
Authority
BR
Brazil
Prior art keywords
estrogen
production
inhibit
effects
human body
Prior art date
Application number
BRPI0408777-1A
Other languages
English (en)
Inventor
Afa Kehaati Palu
Mian Ying Wang
Brett Justin West
Johannes Joseph Westendorf
Claude Jarakae Jensen
Stephen Paul Story
Chen Xing Su
Original Assignee
Morinda Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/396,868 external-priority patent/US20040192761A1/en
Application filed by Morinda Inc filed Critical Morinda Inc
Publication of BRPI0408777A publication Critical patent/BRPI0408777A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/74—Rubiaceae (Madder family)
    • A61K36/746—Morinda
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

"INIBIçãO SELETIVA DA PRODUçãO DE ESTROGêNIO E PROVISãO DE EFEITOS ESTROGêNICOS NO CORPO HUMANO". A aplicação é direcionada para inibir seletivamente a produção de estrogênio e fornecer efeitos estrogênicos em um corpo humano. Um suplemento dietético inclui um produto processado de Morinda citrifolia que é usado para inibir aromatase ou enzimas de aromatase que agem para converter andrógenos a estrógenos, inibir receptores de ligação com estrogênio, e reduzir e/ou regular a produção de estrogênio, assim como reduzir a quantidade de estrogênio produzida no corpo e regular tal produção. O suplemento dietético também fornece efeitos estrogênicos. Os métodos e composições da presente invenção agem de forma eficaz para tratar cânceres dependentes de estrogênio, e particularmente inibir, destruir, e reverter os efeitos dos tumores cancerosos dependentes de estrogênio através da introdução no corpo (por exemplo por ingestão) de uma dosagem segura, predeterminada de uma composição nutracêutica formulada ou que compreende um ou mais produtos processados de Morinda citrifolia por uma duração segura, predeterminada.
BRPI0408777-1A 2003-03-25 2004-03-25 inibição seletiva da produção de estrogênio e provisão de efeitos estrogênicos no corpo humano BRPI0408777A (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US10/396,868 US20040192761A1 (en) 2003-03-25 2003-03-25 Preventative and treatment effects of morinda citrifolia as an aromatase inhibitor
US45835303P 2003-03-28 2003-03-28
US10/808,872 US8501245B2 (en) 2000-12-05 2004-03-24 Selectively inhibiting estrogen production and providing estrogenic effects in the human body
PCT/US2004/009129 WO2004091545A2 (en) 2003-03-25 2004-03-25 Selectively inhibiting estrogen production and providing estrogenic effects in the human body

Publications (1)

Publication Number Publication Date
BRPI0408777A true BRPI0408777A (pt) 2006-03-28

Family

ID=33303842

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0408777-1A BRPI0408777A (pt) 2003-03-25 2004-03-25 inibição seletiva da produção de estrogênio e provisão de efeitos estrogênicos no corpo humano

Country Status (7)

Country Link
US (1) US8501245B2 (pt)
EP (1) EP1605901A4 (pt)
JP (1) JP2007524599A (pt)
AU (1) AU2004229319C1 (pt)
BR (1) BRPI0408777A (pt)
CA (1) CA2520262A1 (pt)
WO (1) WO2004091545A2 (pt)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040192761A1 (en) * 2003-03-25 2004-09-30 Palu Afa Kehaati Preventative and treatment effects of morinda citrifolia as an aromatase inhibitor
US8652546B2 (en) 2007-09-06 2014-02-18 Tahitian Noni International, Inc. Morinda citrifolia based formulations for regulating T cell immunomodulation in neonatal stock animals
US20110171333A1 (en) * 2000-12-05 2011-07-14 Bryant Wadsworth Morinda Citrifolia Based Antioxidant and Antimicrobial Formulations for Improved Color Stability and Increased Shelf Life of Various Meat Products
US20070196527A1 (en) * 2006-02-23 2007-08-23 Jensen Claude J Preventative and treatment effects of Morinda citrifolia on Osteoarthritis and its related conditions
US20110217394A1 (en) * 2000-12-05 2011-09-08 Brett Justin West Iridoid Based Formulations
US20120237626A9 (en) * 2000-12-05 2012-09-20 Palu Afa Kehaati Profiles of lipid proteins and inhibiting HMG-CoA reductase
US8574642B2 (en) 2000-12-05 2013-11-05 Tahitian Noni International, Inc. Antiviral Morinda citrifolia L. based formulations and methods of administration
US6855345B2 (en) * 2001-11-02 2005-02-15 Morinda, Inc. Preventative and treatment effects of Morinda citrifolia on diabetes and its related conditions
US8790727B2 (en) * 2000-12-05 2014-07-29 Tahitian Noni International, Inc. Morinda citrifolia and iridoid based formulations
US7442395B2 (en) * 2002-11-14 2008-10-28 Tahitian Noni International, Inc. Formulation for treating candidiasis using Morinda citrifolia
US20110160057A1 (en) * 2001-11-14 2011-06-30 Bryant Wadsworth Morinda Citrifolia Based Antimicrobial Formulations
US20070259060A1 (en) * 2003-08-12 2007-11-08 Mian-Ying Wang Formulations and Methods for Treating Breast Cancer with Morinda Citrifolia and Methylsulfonymethane
US20060204601A1 (en) * 2005-03-09 2006-09-14 Palu Afa K Formulations and methods for preventing and treating substance abuse and addiction
US20060280818A1 (en) * 2005-05-26 2006-12-14 Palu Afa K Nicotinic acetylcholine receptor antagonist
US20070166417A1 (en) * 2005-11-29 2007-07-19 Palu Afa K Formulation and Methods for Use of Morinda Citrifolia Seed Oil
US20070184137A1 (en) * 2005-11-29 2007-08-09 Palu Afa K Morinda Citrifolia L. Based Formulations for Inhibiting Matrix Metalloproteinase Enzymes
US20070154579A1 (en) * 2005-11-29 2007-07-05 Palu Afa K Morinda Citrifolia Based Formulation And Methods For Weight Management
US20070281903A1 (en) * 2006-05-04 2007-12-06 Palu Afa K Morinda Citrifolia-Based Formulation 5-LOX And 15-LOX
US8025910B2 (en) 2006-05-12 2011-09-27 Tahitian Noni International, Inc. Method and composition for administering bioactive compounds derived from Morinda citrifolia
US8535741B2 (en) 2006-05-12 2013-09-17 Morinda, Inc. Method and composition for administering bioactive compounds derived from Morinda citrifolia
US20080317890A1 (en) * 2007-06-21 2008-12-25 Claude Jarakae Jensen Method for treating visual impairment through the prophylactic administration of a morinda citrifolia-based naturaceutical
US20090196944A1 (en) * 2008-02-01 2009-08-06 Brad Rawson Methods of Manufacture of Morinda Citrifolia Based Compositions for Treatment of Anti-Inflammatory Diseases through Inhibition of Cox-1, Cox-2, Interleukin -1beta, Interleukin-6, TNF-alpha, HLE, and iNOS
US20110206786A1 (en) * 2010-02-23 2011-08-25 Brett Justin West Acai and Iridoid Based Formulations
JP5668001B2 (ja) * 2012-03-05 2015-02-12 丸善製薬株式会社 皮膚化粧料及び頭髪化粧料
EP3159003A3 (en) 2015-10-23 2017-07-19 Universiti Putra Malaysia Composition for enhancing bone growth, preventing bone resorption disorders and for joint health
CN111534483B (zh) * 2020-05-23 2020-12-18 广东壹加再生医学研究院有限公司 一种胰岛素样生长因子结合蛋白7激活剂在人脐带间充质干细胞成软骨分化中的应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2057332T3 (es) * 1990-01-16 1994-10-16 Boots Pharma Gmbh Utilizacion de un acido hidroxioctadecadieno sus acidos oxidados en forma ceto asi como sus derivados para terapia de enfermedades dependientes del estrogeno asi como las combinaciones farmaceuticas que lo contengan.
AU2783092A (en) * 1991-10-26 1993-05-21 East Riding Laboratories Limited Composition for topical application
US5708038A (en) * 1996-06-13 1998-01-13 Univera Pharmaceuticals, Inc. Method of using aloe vera as a biological vehicle
EP0979074A4 (en) * 1997-05-01 2003-07-09 Novogen Inc TREATMENT OR PREVENTION CLIMATE ACTION SYMPTOMS AND OSTEOPOROSIS
US7018662B2 (en) * 2001-04-17 2006-03-28 Morinda, Inc. Palliative effects of morinda citrifolia oil and juice
CN1685053A (zh) * 2002-09-23 2005-10-19 加拿大农业部 从植物生物质提取、纯化和转化类黄酮化合物

Also Published As

Publication number Publication date
US20040224038A1 (en) 2004-11-11
EP1605901A2 (en) 2005-12-21
AU2004229319A1 (en) 2004-10-28
US8501245B2 (en) 2013-08-06
AU2004229319B2 (en) 2008-02-07
EP1605901A4 (en) 2007-07-04
WO2004091545A3 (en) 2006-05-18
JP2007524599A (ja) 2007-08-30
AU2004229319C1 (en) 2008-09-18
CA2520262A1 (en) 2004-10-28
WO2004091545A2 (en) 2004-10-28

Similar Documents

Publication Publication Date Title
BRPI0408777A (pt) inibição seletiva da produção de estrogênio e provisão de efeitos estrogênicos no corpo humano
Remely et al. Therapeutic perspectives of epigenetically active nutrients
Busch et al. Epigenetic activities of flavonoids in the prevention and treatment of cancer
Fang et al. Dietary polyphenols may affect DNA methylation
Chen et al. Flaxseed and its components reduce metastasis after surgical excision of solid human breast tumor in nude mice
AR018924A1 (es) Composicion para la prevencion y/o tratamiento de osteoporosis y alteraciones debidas al sindrome de menopausia
SI1556058T1 (sl) Farmacevtski sestavki, ki obsegajo estetrolne derivate, za uporabo pri zdravljenju raka
Lee et al. Cancer chemoprevention by traditional chinese herbal medicine and dietary phytochemicals: targeting nrf2-mediated oxidative stress/anti-inflammatory responses, epigenetics, and cancer stem cells
ES2189784T3 (es) Procedimiento para el tratamiento de enfermedades relacionadas con adrogenos.
TW240215B (pt)
BRPI0518315B8 (pt) compostos de tiazol que modulam a atividade da proteína hsp90, métodos de inibição, tratamento e indução associados e composição farmacêutica
Soares et al. Up-regulation of Nrf2-antioxidant signaling by Açaí (Euterpe oleracea Mart.) extract prevents oxidative stress in human endothelial cells
EP2004177A4 (en) NITROFURAN COMPOUNDS FOR THE TREATMENT OF CANCER AND ANGIOGENESIS
Atolani et al. Chemical composition and antioxidant potentials of Kigelia pinnata root oil and extracts
US20210308148A1 (en) Pharmaceutical use
WO2004066962A3 (en) Method of treatment of prostate cancer and composition for treatment thereof
WO2007131767A3 (en) Novel actives against prostate carcinoma
EA200700247A1 (ru) Композиции, содержащие ингибиторы 5-альфа-редуктазы и serm, и способы их применения
Andrijauskaite et al. Natural Anticancer Agents: Modifying the Epigenome to Prevent and Treat Cancer
EP1660108A4 (en) COMPOSITION COMPRISING AN EXTRACT OF NOTOGINSENG RADIX / I AS ACTIVE INGREDIENT FOR PREVENTING AND TREATING ARTHRITIS
ID26965A (id) Obat untuk mencegah dan/atau mengobati kanker payudara, yang mengandung inhibitor aromatase steroid
Katz et al. Isoflavones and gamma irradiation inhibit cell growth in human salivary gland cells
WO2007050599A3 (en) Ginkgolides in the treatment and prevention of ovarian cancer
Illam et al. Targeting histone onco-modifications using plant-derived products
CA2325041A1 (en) Ultra-vit. plus

Legal Events

Date Code Title Description
B08F Application fees: application dismissed [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE.

B15K Others concerning applications: alteration of classification

Free format text: ALTERADA DA INT. CL. A61K 35/78.

Ipc: A61K 36/746 (2006.01), A61K 36/74 (2006.01), A61P

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: NAO APRESENTADA A GUIA DE CUMPRIMENTO DE EXIGENCIA. REFERENTE AS 5A E 8A ANUIDADES.